The White House announced on August 31, 2026 that nine additional pharmaceutical manufacturers — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB — had agreed to align U.S. drug prices with the lowest prices paid by other developed nations under the administration’s most-favored-nation (MFN) pricing framework. The White House said the addition brings the total number of companies with MFN agreements to 26, covering what it describes as 89% of the U.S. branded drug market. One of the nine companies, CSL, headquartered in King of Prussia, Pennsylvania,
What CSL Agreed To
CSL entered two separate agreements: one with the U.S. Department of Health and Human Services on Medicaid pricing, and an Onshoring Agreement with the U.S. Department of Commerce. Under the HHS agreement, CSL committed to provide state Medicaid programs access to its current medicines at prices comparable to other developed nations, and to price newly launched therapies similarly for all U.S. payers, across its CSL Behring, CSL Seqirus, and CSL Vifor businesses, which include therapies for hemophilia and immune deficiencies, influenza vaccines, and iron-deficiency treatments.
The onshoring agreement builds on a previously announced $1.5 billion expansion of CSL’s manufacturing site in Kankakee, Illinois, to expand immunoglobulin and albumin production capacity, which the company expects will create at least 300 pharmaceutical manufacturing jobs and roughly 800 construction and related jobs.
Global Chief Commercial Officer Diego Sacristan said: “At CSL, our focus has always been the patients who depend on our therapies. These agreements provide a sustainable and stable access framework to important medicines for people living with rare diseases and serious conditions while strengthening the manufacturing capabilities, supply infrastructure and scientific innovation required to deliver those therapies reliably.” CSL says it employs approximately 19,000 people across 44 states, about 60% of its global workforce.
The Deal’s Broader Scale
Beyond CSL, the nine companies — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB — collectively committed to at least $19.6 billion in U.S. manufacturing investment, and several agreed to donate strategic drug reserves, including UCB (163 tons of levetiracetam), Sun Pharma (71.4 tons of clindamycin and 6.75 tons of doxycycline), Teva (45 metric tons of metronidazole and 4.8 tons of amlodipine), and Astellas (25 kg of tacrolimus).
About CSL
CSL is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including therapies that treat hemophilia and immune deficiencies, vaccines that help prevent influenza, and treatments in iron deficiency, dialysis and nephrology. Through its businesses CSL Behring, CSL Seqirus and CSL Vifor, CSL provides products to patients in more than 100 countries and employs almost 29,000 people worldwide. CSL is driven by its promise to develop and deliver innovations that improve and save lives. CSL’s purpose is grounded in patient focus, innovation, integrity, collaboration and superior performance.
CSL today employs approximately 19,000 people across 44 U.S. states, representing about 60 per cent of the company’s global workforce. Since 2018, CSL has invested more than $3.1 billion in its U.S. operations, creating more than 6,500 American jobs and expanding its manufacturing, research and plasma collection capabilities nationwide.
